Isai Peimer

Directeur/Bestuurslid bij

Adheron Therapeutics, Inc.

48 jaar

Connecties 94

Health Technology

Finance

Consumer Services

Profiel

Isai Simon Peimer is currently a Director at Adheron Therapeutics, Inc. He previously held positions as an Independent Director at Inotek Pharmaceuticals Corp., a Managing Director at MedImmune Ventures, Inc., and an Independent Director at Ambit Biosciences Corp.
He also served as a Director at Armaron Bio Ltd. and Corridor Pharmaceuticals, Inc. Prior to his roles in the biotech industry, Isai worked as an Investment Banker at JPMorgan Securities LLC.
He obtained his undergraduate degree from Emory University in 1998 and later earned an MBA from the Tuck School of Business at Dartmouth in 2005.
Mr. Peimer's current job is Director at Adheron Therapeutics, Inc.

Actieve functies van Isai Peimer

Bedrijven	Functie	Begin
Adheron Therapeutics, Inc. Adheron Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company	Directeur/Bestuurslid	-

Alle actieve functies van Isai Peimer

Eerdere bekende functies van Isai Peimer

Bedrijven	Functie	Einde
Surveyor Capital Ltd. Surveyor Capital Ltd. Investment Trusts/Mutual FundsMiscellaneous Surveyor Capital is a global, multi-manager equities strategy and is one of Citadel’s three fundamental equities businesses. Their sector-aligned investment teams conduct deep fundamental research, developing an independent view on the companies they cover. They are specialists in their industries and experts in their coverage, building trusted relationships with many corporate management teams. The firm's investment teams leverage Citadel’s proprietary, market-neutral risk framework with the aim of building portfolios that minimize broad market exposures. Using this insight, they act on their investment theses and scale their risk-taking with confidence.	Analyst-Equity	01-12-2023
Inotek Pharmaceuticals Corp. Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Engages in the development, discovery and commercialization of therapies for glaucoma and other diseases of the eye	Directeur/Bestuurslid	04-04-2016
MedImmune Ventures, Inc. MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors.	Private Equity Investor	01-01-2016
AMBIT BIOSCIENCES CORP	Directeur/Bestuurslid	10-11-2014
JPMorgan Securities LLC JPMorgan Securities LLC Investment Banks/BrokersFinance Provides brokerage services	Corporate Officer/Principal	01-07-2008

Ervaring van Isai Peimer in detail bekijken

Opleiding van Isai Peimer

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Isai Peimer in detail bekijken

Connecties

Eerstegraads connecties

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit	10
JPMorgan Securities LLC JPMorgan Securities LLC Investment Banks/BrokersFinance Provides brokerage services	Finance
Inotek Pharmaceuticals Corp. Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Engages in the development, discovery and commercialization of therapies for glaucoma and other diseases of the eye	Health Technology
MedImmune Ventures, Inc. MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors.	Finance
Ambit Biosciences Corp. Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Develops and sells molecule kinase inhibitors for the treatment of cancer	Health Technology
Adheron Therapeutics, Inc. Adheron Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company	Health Technology
Emory University Emory University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Surveyor Capital Ltd. Surveyor Capital Ltd. Investment Trusts/Mutual FundsMiscellaneous Surveyor Capital is a global, multi-manager equities strategy and is one of Citadel’s three fundamental equities businesses. Their sector-aligned investment teams conduct deep fundamental research, developing an independent view on the companies they cover. They are specialists in their industries and experts in their coverage, building trusted relationships with many corporate management teams. The firm's investment teams leverage Citadel’s proprietary, market-neutral risk framework with the aim of building portfolios that minimize broad market exposures. Using this insight, they act on their investment theses and scale their risk-taking with confidence.	Miscellaneous
Armaron Bio Ltd. Armaron Bio Ltd. Electronic Equipment/InstrumentsElectronic Technology Develops cardioprotection and neuroprotection small molecules to reduce tissue damage for heart attacks	Electronic Technology
Corridor Pharmaceuticals, Inc. Corridor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical products	Health Technology
Tuck School of Business at Dartmouth Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services